IL33 and lung carcinoma: While a study reported that IL-33-induced activation of ILC2s may lead to the reduced function of lung NK cells, others found that ILC2s could interact with DCs and T cells to augment the antitumor function in a variety of cancers including lung cancer (111, 112).